BOULDER, Colo.--(BUSINESS WIRE)--Jun. 13, 2013--
Clovis Oncology, Inc. (Nasdaq: CLVS), announced today the addition of
two new members to its Board of Directors, Ginger Graham and Keith
Flaherty, M.D.
“We are delighted to add these two gifted individuals to our Board of
Directors as the Company matures into a later-stage developer of
oncology products and ultimately a commercial organization,” said
Patrick J. Mahaffy, president and CEO of Clovis Oncology. “Ginger is a
widely respected and well-known healthcare executive with significant
CEO- and Board-level experience. Keith has highly-relevant experience as
a clinician developing innovative oncology products, in particular
targeted therapies with companion diagnostics. We are really pleased
that they have chosen to join us.”
Ginger Graham is the President and CEO of Two Trees Consulting,
where she coaches first-time CEOs of public and private companies. For
the last four years, she has been a senior lecturer at Harvard
University and a faculty member in its Entrepreneurship Unit. Ms. Graham
is the former President and CEO of Amylin Pharmaceuticals, a
biopharmaceutical company based in San Diego, CA focused on diabetes and
obesity. Previously, Ms. Graham was Group Chairman, Office of the
President for Guidant Corporation. Ms. Graham serves on the Boards of
Directors for Walgreen Co., Genomic Health, Inc., Surefire Medical,
Elcelyx Therapeutics Inc., Proteus Biomedical and Circle of Life Hospice
Foundation. Ms. Graham has a Bachelor of Science, Agriculture with high
honors from the University of Arkansas and a Master in Business
Administration with distinction from Harvard Business School.
Keith Flaherty, M.D. is an Associate Professor of Medicine at
Harvard Medical School, Associate Physician of Medicine,
Hematology/Oncology at Massachusetts General Hospital, and Director of
the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts
General Hospital Cancer Center. Dr. Flaherty is also the Deputy Chair
for Biomarker Sciences and the Chair of the Developmental Therapeutics
Committee in the Eastern Cooperative Oncology Group. Dr. Flaherty has
served as Principal Investigator for numerous first-in-human clinical
trials with novel, targeted therapies, including the first in-human
trials of the first prospectively developed selective BRAF inhibitors
for metastatic melanoma. Dr. Flaherty has a Bachelor of Science from
Yale University and medical degree from Johns Hopkins University. Dr.
Flaherty trained in internal medicine at Brigham and Women’s Hospital
and completed a medical oncology fellowship at the University of
Pennsylvania.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops diagnostic tools that direct a
compound in development to the population that is most likely to benefit
from its use. Clovis Oncology is headquartered in Boulder, Colorado, and
has additional offices in San Francisco, California and Cambridge, UK.
To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve substantial risks and uncertainties
that could cause our clinical development programs, future results,
performance or achievements to differ significantly from those expressed
or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in the
initiation of future clinical trials, availability of data from ongoing
clinical trials, expectations for regulatory approvals, and other
matters that could affect the availability or commercial potential of
our drug candidates. Clovis Oncology undertakes no obligation to update
or revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well as
risks relating to the business of the company in general, see Clovis
Oncology’s Annual Report on Form 10-K for the year ended December 31,
2012 and its other reports filed with the Securities and Exchange
Commission.
Source: Clovis Oncology, Inc.
Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
asussman@clovisoncology.com
or
Breanna
Burkart, 303-625-5023
bburkart@clovisoncology.com